Unity Biotechnology Inc. (UBX) stock is nearly perfect except the valuation

The closing price of Unity Biotechnology Inc. (NASDAQ: UBX) was $2.40 for the day, up 5.73% from the previous closing price of $2.27. In other words, the price has increased by $+0.1300 from its previous closing price. On the day, 262934 shares were traded. UBX stock price reached its highest trading level at $2.4300 during the session, while it also had its lowest trading level at $2.2800.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Ratios:

Our analysis of UBX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 6.10 and its Current Ratio is at 6.10. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.17.

Upgrades & Downgrades

On November 10, 2021, Mizuho Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $5 to $7.

Citigroup Upgraded its Sell to Buy on June 28, 2021, while the target price for the stock was maintained at $6.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 03 when Ghosh Anirvan sold 1,099 shares for $2.40 per share. The transaction valued at 2,638 led to the insider holds 97,222 shares of the business.

Ghosh Anirvan sold 13,706 shares of UBX for $6,579 on Sep 14. The Chief Executive Officer now owns 983,210 shares after completing the transaction at $0.48 per share. On Sep 14, another insider, Dananberg Jamie, who serves as the Chief Medical Officer of the company, sold 10,923 shares for $0.48 each. As a result, the insider received 5,243 and left with 661,213 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 7.22 while its Price-to-Book (P/B) ratio in mrq is 0.03.

Stock Price History:

Over the past 52 weeks, UBX has reached a high of $24.80, while it has fallen to a 52-week low of $2.09. The 50-Day Moving Average of the stock is 3.3563, while the 200-Day Moving Average is calculated to be 6.9703.

Shares Statistics:

UBX traded an average of 695.96K shares per day over the past three months and 373.01k shares per day over the past ten days. A total of 14.19M shares are outstanding, with a floating share count of 13.93M. Insiders hold about 1.20% of the company’s shares, while institutions hold 46.10% stake in the company. Shares short for UBX as of Oct 13, 2022 were 112.45k with a Short Ratio of 0.19M, compared to 146.93k on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 0.80% and a Short% of Float of 0.81%.

Earnings Estimates

The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of -$1.65 for the current quarter, with a high estimate of -$1.1 and a low estimate of -$1.94, while EPS last year was -$3. The consensus estimate for the next quarter is -$1.69, with high estimates of -$1.3 and low estimates of -$1.9.

Analysts are recommending an EPS of between -$7 and -$8.6 for the fiscal current year, implying an average EPS of -$8.06. EPS for the following year is -$7.88, with 3 analysts recommending between -$5.9 and -$9.4.